Mark Rosen1, Sarah Englander1, Harish Poptani1, Evan Siegelman1, James Gimpel2, Dena Flamini2, Matthew Parris3, Bill Sasiela3, Bruce Hillman4,5
1Radiology, University of Pennsylvania, Philadelphia, PA, USA; 2American College of Radiology Imaging Network, Philadelphia, PA, USA; 3Aegerion, Inc., Bridgewater, NJ, USA; 4Radiology, University of Virginia, Charlottesville, VA, USA; 5American College of Radiology, Phialdelphia, PA, USA
A fifteen-center multisite trial of hepatic MRI and MRS for liver fat determination in 470 subjects was performed for the phase II evaluation of the MTP inhibitor AEGR-733. Sites performed single voxel MRS and multiple dual-echo GRE imaging for quantifying hepatic fat. Both academic and non-academic sites were included. Analyzable MRS data was obtained in 96.3% of cases. Fully compliant MRI data sets were obtained in 90.0% of cases. Both academic and non-acadeimc sites performed equally well with respect to MRS quality. Academic sites submitted a higher percentage of protocol-compliant MRI data sets than did non-academic sites.